SEC Form 4	
------------	--

 \square

UNITED STATES SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

OMB APPROVAL

OMB Number:	3235-0287						
Estimated average burden							
hours per response:	0.5						

Check this box if no longer subject to
Section 16. Form 4 or Form 5
obligations may continue. See
Instruction 1(b).

FORM 4

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

1. Name and Ad <u>Tierney Da</u>	dress of Reporting tivid S	Person*	2. Issuer Name and Ticker or Trading Symbol <u>CATALYST PHARMACEUTICALS, INC.</u> [CPRX]		ationship of Reporting Pe (all applicable) Director		
(Last) 355 ALHAM	Last) (First) (Middle) 355 ALHAMBRA CIRCLE, SUITE 801		3. Date of Earliest Transaction (Month/Day/Year) 12/06/2022	-	Officer (give title below)	Other (specify below)	
(Street) CORAL GABLES (City) (State) (Zip)			4. If Amendment, Date of Original Filed (Month/Day/Year)	 6. Individual or Joint/Group Filing (Check Applicable Line) X Form filed by One Reporting Person Form filed by More than One Reporting Person 			
		Table I - Non-De	erivative Securities Acquired, Disposed of, or Benef	icially	Owned		

1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transa Code (8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)		5. Amount of Securities Beneficially Owned Following Reported	(D) or Indirect	7. Nature of Indirect Beneficial Ownership (Instr. 4)	
			Code	v	Amount	(A) or (D)	Price	Transaction(s) (Instr. 3 and 4)		(1130.4)
Common Stock, Par Value \$0.001 per share	12/06/2022		М		1,334	Α	(1)	309,541	D	

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities) 6. Date Exercisable and 8. Price of Derivative Security (Instr. 5) 1. Title of 3. Transaction 3A. Deemed 5. Number 7. Title and 9. Number of 10. 11. Nature 7. Title and Amount of Securities Underlying Derivative Sec (Instr. 3 and 4) Derivative Security (Instr. 3) Conversion or Exercise Price of Execution Date, if any (Month/Day/Year) Transaction Code (Instr. 8) Expiration Date (Month/Day/Year) Ownership Form: of Indirect Beneficial Date (Month/Day/Year) derivative Derivative Securities Direct (D) Securities Beneficially Ownership Beneficially Owned Following Reported Transaction(s) (Instr. 4) Acquired (A) or Disposed Derivative Security or Indirect (I) (Instr. 4) Security (Instr. 4) of (D) (Instr. 3, 4 and 5) Amount or Number Expiration Date Date or Shares ν (D) Code (A) Exercisable Title Restricted Commo 1,334 Stock Units (2)(3) 12/06/2022 Μ 1,334 \$<mark>0</mark> 295,500 D Stock

Explanation of Responses:

1. Each restricted stock unit represents a contingent right to receive one share of the Registrant's common stock upon vesting.

2. Derivative securities vested in equal tranches, 1/3rd on December 2, 2020, 1/3rd on December 2, 2021 and 1/3rd on December 2, 2022.

3. Shares of common stock are required to be delivered to the Reporting Person within sixty days of vesting. The final tranche of shares was delivered on December 6, 2022.

/s/ David S. Tierney

** Signature of Reporting Person

Date

12/08/2022

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).

** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.